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1. Introduction 
The nervous system is a stimulating target for regenerative medicine. Parkinson’s disease 
(PD), which afflicts over a 1 million people in the US, is a chronic neurodegenerative 
disorder characterized by the degeneration and death of midbrain neurons that produce the 
neurotransmitter dopamine (DA), resulting in tremors at rest, an inability to initiate or 
complete routine movements, muscle rigidity, postural instability, and lack of facial 
expression. Although the etiology of idiopathic PD is not known, several predisposing 
factors for the dopaminergic depletion associated with the disease have been suggested, 
including programmed cell death, viral infection, and environmental toxins. 
DA neurons, in the substantia nigra pars compacta, play a prominent role in the control of 
many brain functions, such as voluntary movements and many behavioral processes 
(Maxwell & Li, 2005). These neurons can be identified via the expression of some specific 
transcription factors, including Engrailed 1 (EN1), PITX3, NURR1, and LMX1b, which are 
also very important in the development of DA neurons (Smidt et al., 2003). 
2. Current therapeutic strategies for PD 
2.1 Drug therapy and DBS 
Current established therapeutic strategies for PD patients comprise drug treatments such as L-
dopa (a precursor of dopamine), DA agonists, enzyme inhibitors and deep brain stimulation in 
the thalamus, subthalamic nucleus and globus pallidus (Figure 1). However, these treatments 
are effective in early stage and can temporarily ameliorate symptoms and cannot cure the 
disease. Therefore, there is a need for novel therapeutic approaches which one of them is to 
regenerate the damaged tissue. Since direct regeneration of brain tissues is difficult to achieve, 
an alternate supply of neural cells is required in order to attain any therapeutic goal. Cell 
replacement therapy (neurotransplantation) has been suggested to have a great potential for 
restorative therapy in PD (Freed et al., 2001; Hagell & Brundin, 2001; Olanow et al., 2003). 
2.2 Cell replacement therapy 
2.2.1 Foetal mesencephalic tissue 
Transplantation of human foetal ventral mesencephalic tissues into the putamen or caudate 
nucleus of PD patients has been adopted as a potentially curative cell replacement therapy 
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Fig. 1. In the normal brain, DA neurons located in the substantia nigra send their axons to 
the striatum (i.e. the putamen and caudate nucleus). In the PD brain, the main pathology 
leading to motor symptoms is a degeneration of these neurons causing a loss of DA in the 
striatum. Drug treatment, deep brain stimulation and embryonic mesencephalic tissue 
transplantation are current therapeutic approaches for PD. Transplantation of DA neurons 
generated from embryonic stem cells has been suggested to restore striatal dopaminergic 
innervation thereby alleviating PD symptoms. 
with long term survival of grafted cells (Kordower et al., 2008a; Li et al., 2008; Mendez et al., 
2008). A bulk of experimental and clinical studies have shown functional efficacy of grafting of 
embryonic mesencephalic tissue into the striatum and a biological mechanism underlying the 
observed improvement. In spite of promising results of foetal mesencephalic cells 
transplantation, so far numerous unresolved problems remain to be addressed, such as ethical 
and religious questions and logistics of acquiring foetal tissues, graft-induced off-medication 
dyskinesias in up to 56% of transplanted patients (Freed et al., 2001; Hagell et al., 2002; Olanow 
et al., 2003) and inadequate foetal tissues for transplantation (since treatment of a single PD 
patient requires DA neurons from six to ten human aborted foetuses). To bypass these 
difficulties, neurons with a DA phenotype generated from embryonic stem cells (ESCs) could 
be employed as a practical and effective alternative for foetal brain tissues for transplantation. 
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2.2.2 Embryonic stem cells 
ESCs, derived from the inner cell mass of early post-fertilization blastocysts, are capable of 
unlimited cell expansion in vitro while maintaining their pluripotency. These characteristics 
of ESCs make them an excellent source of functional differentiated cells for cell replacement 
therapy of neurodegenerative medicine such as PD, provided that reliable means of 
inducing differentiation to specific cell types can be achieved. After differentiation, ESCs-
derived neurons have to work at least similar to those in embryonic mesencephalic 
transplantations. Therefore, these neurons have to achieve the following requirements to 
improve PD markedly after grafting: (i) release DA and exhibit the molecular, 
morphological and electrophysiological properties of midbrain DA neurons (Mendez et al., 
2005; ,Isacson et al., 2003); (ii) reverse motor deficits in animal models resembling the 
symptoms in patients; (iii) enable 100000 or more grafted DA neurons to survive long term 
in each human putamen (Hagell & Brundin, 2001); (iv) re-establish a dense terminal 
network throughout the striatum; and (v) become functionally integrated into host neural 
circuitries (Piccini et al., 2000).  
Two basic strategies can be employed to use ESCs as a cell source for cell replacement 
therapy: they can be used without any previous in vitro differentiation based on the 
hypothesis that regional microenvironment is the best inductive cue to obtain the required 
cell type. An alternative strategy would be to partly or totally differentiate ESCs into the 
desired cells based on the hypothesis that the host tissue-derived inductive cues are not 
sufficient to achieve this and to avoid tumor formation at the same time. 
Although it has been reported that transplantation of undifferentiated ESCs into the 
midbrain parkinsonian rats resulted in dopaminergic differentiation of these cells, high rate 
of differentiated cells were serotonergic neurons (a relation of 2:1 of dopaminergic to 
serotonergic neurons). Due to this fact that serotonergic neurons in grafts are responsible for 
off-medication dyskinesias in clinical transplantation studies (Carlsson et al., 2007), it is 
rather unlikely that the resulting cell composition is well suited for successful 
transplantation. A more limiting issue was that 20% of the grafted animals had to be 
sacrificed before the defined study endpoint because of teratoma formation. Although 
several strategies have been employed to reduce the risk of tumor formation (Chung et al., 
2006; Li et al., 1998; Schuldiner et al., 2003), the use of undifferentiated ESCs remains an 
unsafe strategy. 
3. In vitro neural differentiation of ESCs 
The in vitro differentiation of ESCs toward dopaminergic neurons has followed different 
culture protocols in the presence of various combinations of growth factors and signaling 
molecules. By studying these signaling molecules present in the midbrain 
microenvironment during development and in the adult, and which key regulatory 
transcription factors the cells express, protocols for controlling ex vivo dopaminergic neurons 
differentiation can be achieved. 
3.1 The major signaling molecules  
Retinoic acid (RA) is one of the most important signaling molecules that promote neuralization 
in embryos and later in development (Bain et al., 1996; Guan et al., 2001; Diez del Corral & 
Storey, 2004). All-trans RA, which can bind to both RAR subtypes, is commonly employed to 
induce neuronal differentiation in vitro. RA induces a pan-neuronal differentiation and the cell 
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population obtained after application of this differentiation factor is relatively heterogeneous 
(Carpenter et al., 2001, Schuldiner et al., 2000). Takahashi et al showed that cells cultured with 
RA and fetal bovine serum (FBS) expressed markers for GABAergic, dopaminergic, and 
cholinergic neuronal phenotypes at low levels (Takahashi et al., 1999).  
Wnt3a is another signaling molecule recently shown to play a key role in regulating 
neurogenesis in the adult brain. In vivo expression of a Wnt3a inhibitor reduced 
neurogenesis in the adult hippocampus. By contrast, Wnt3 overexpression in vivo and in 
vitro increased neuronal differentiation (Lie et al., 2005). However, Wnt3’s overexpression in 
vitro resulted in a mixed culture of glia and neurons. Also, it is yet to be determined whether 
Wnt signaling induces a specific neuronal phenotype or serves as a nonspecific, pan-
neuronal signal. 
BMP is another inhibitory signal found within neural differentiation. It has been shown that 
the overexpression of the BMP antagonist Noggin increased neural differentiation in 
neurosphere culture (Setoguchi et al., 2004). BMP signaling activation in undifferentiated 
cells can result in extraembryonic endoderm committed cells and epidermogenesis. In 
addition, it has been reported that BMP4 can induce mesodermal differentiation. Noggin is a 
well characterized BMP2 and BMP4 antagonist and has been shown as neural inducer in 
Xenopus embryos (Niknejad et al., 2010). Since ESCs are pluripotent and susceptible to give 
rise to all three germ layers, blocking BMP signaling using its antagonist noggin can induce 
neuronal differentiation by its inhibitory effects on the mesodermal, endodermal, and 
epidermal fate of ESCs (Gerrard et al., 2005). In addition, inhibiting Notch and BMP-2 
signaling may synergistically enhance neuronal differentiation more than suppressing either 
alone. 
However, using these signaling molecules solely result in the mixed population of neural cells, 
indicating that there are most likely other signals found within the in vivo microenvironment 
that work in conjunction with each other to ensure a neuronal cell fate commitment. 
3.2 Current protocols for DA differentiation 
Numerous methods have been employed to differentiate mouse and human ESCs into 
neural cells. Mouse ESCs can be induced into neural progenitors by several methods, such 
as the use of retinoic acid (RA) treatment of embryoid body (EB) (Bain et al., 1995; Wichterle 
et al., 2002), a multistep-induction and selection culture (Lee et al., 2000), an adherent 
monoculture system in serum-free medium (Ying et al., 2003), and a co-culture with stromal 
cell types (Kawasaki et al., 2000, Barberi et al., 2003). Human ESCs can be induced into the 
neural lineages using similar methodologies: through the formation of EBs in suspension 
(Zhang et al., 2006), an adherent monoculture system (Benzing et al., 2006), with co-culture 
(Ueno et al., 2006) and through spontaneous differentiation of human ESCs (Zhang et al., 
2001, Reubinoff et al., 2001). Each of these protocols has its pros and cons. In the following 
part, the most used procedures for neural differentiation of ESCs will be described.  
3.2.1 Embryoid body formation 
The well-studied system for neuronal differentiation of ESCs involves the formation of three-
dimensional structures called embryoid bodies (EBs) that, to a limited extent, simulates 
embryonic development in vivo (Itskovitz-Eldor et al., 2000). EBs are spontaneously generated 
when ESCs are cultured in suspension cultures without LIF or serum, in either non-adhesive 
dishes or hanging drops. The cells in EB begin to differentiate into a heterogeneous  
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Fig. 2. Schemata depicting steps of three protocols by which ESCs are induced to adopt the 
DA Lineage. 
population of progenitor cells that can form all cell types from the three germ layers, such as 
skeletal muscle, cardiac, hematopoietic and neuron-like cells. Therefore, spontaneous 
differentiation of EBs yields only a small fraction of cells with neural lineages. By using 
different morphogens and growth factors during EB formation, a higher fraction of neural 
cells can be produced (Figure 2). 
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After transfer of EBs from a low attachment plate into a normal adhesion plate, the EBs form 
neuroepithelial cells that organize into neural tube like rosettes. After dissociation of 
neuroepithelial cells and addition of neural differentiation medium, which consists of 
BDNF, GDNF, AMP, and ascorbic acid, DA differentiation begins 3–4 weeks after the initial 
treatment of ESCs (Yan et al., 2005). 
EB formation method is still commonly used with the addition of the other supplementary 
to media such as growth factors. Bain et al were the first to show that RA can induce neural 
differentiation in EBs derived from mouse ESCs, i.e. a high proportion of the resulting cells 
expressed neuronal markers and had neuronal properties (Bain et al., 1995). In this work, 
EBs were cultured with RA for 4 days and then plated on laminin-coated dishes. The cells 
expressed neuronal markers beta-tubulin III and NF-M as well as neural-related genes such 
as transmitter synthesizing genes glutamic acid decarboxylase (GAD), TH, transmitter 
receptor subunits GluRs, and a cytoskeletal subunit, NF-L.  
RA applied to ESCs can induce concentration-dependent differentiation of neural cells. 
Okada et al tested the effects of different concentrations of RA on the neural differentiation 
of mouse ESCs (Okada et al., 2004). Lower RA levels (10-8M) were found to induce neural 
progenitor cells from ESCs, indicated by the high protein expression of the neural precursor 
marker nestin and low expression of neuronal and glial markers beta-tubulin III and GFAP, 
respectively. In contrast, high levels of RA (2 X 10-6 M) decreased the expression of nestin 
while increasing beta-tubulin III and GFAP levels. These results are consistent with other 
studies demonstrating differentiation of neural progenitors at high RA concentrations 
(Wichterle., 2002, Bain et al., 1996). RA also directs neural differentiation in human ESCs 
derived-EB cultures (Guan et al., 2001). The addition of RA and nerve growth-factor (NGF) 
increased the rate of neuronal cells that formed within human ESC-derived EBs (Schuldiner 
et al., 2001). However, RA is a strong teratogen and should therefore be used at lower doses 
to prevent toxicity. 
One strategy to direct mouse and human ESCs into "midbrain dopaminergic" neurons is 
through formation of EBs, followed by the combined addition of Shh and FGF-8 and at a 
later stage ascorbic acid (AA) (Lee et al., 2000). Using this method, 34% of the resulting beta-
tubulin III positive neurons derived from mouse ESCs were TH positive. To shorten 
induction protocol time, Lau et al cultured EBs in KO DMEM supplemented with EGF, FGF-
2, and ascorbic acid (Lau et al., 2006). After 3 days, EBs were plated on gelatin-coated dishes 
and cultured with DMEM/F12 containing EGF, FGF-8, Shh, and ascorbic acid. Cells were 
subsequently cultured in Neurobasal medium with ascorbic acid. This method generated 
approximately 40% DA neurons, characterized by their expression of dopamine transporter 
DAT in 14 days. This chemically defined system for ESCs derivation of DA neurons may be 
advantageous compared to the co-culturing method, which will be discussed in the next 
part, as it reduces exposure to animal-derived components and allows for easier 
determination of factors that influence cell fate. 
Another strategy to obtain "midbrain dopaminergic" neurons is the growth of EBs in a 
conditioned medium with a human hepatocarcinoma cell line followed by conventional 
serum- free culture in a medium containing bFGF (Schulz et al., 2004, Schulz et al., 2003), or 
by co-culturing them with telomerase-immortalized fetal midbrain astrocytes (Roy et al., 
2006). EBs plated on tissue culture dishes and in the presence of serum-free ITSF medium 
showed induced differentiation toward dopaminergic precursors within 10 days. In the next 
step, the cells were transferred to polyornithine/laminin-coated dishes and exposed to a 
new medium supplemented with FGF2 and Shh (Roy et al., 2006). Withdrawal of these 
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factors, but the addition of BDNF, GDNF, and FBS, yields dopaminergic neurons that are 
TH positive. The majority of TH positive cells expressed simultaneously G-protein gated 
inwardly rectifying potassium channel type 2 (Sonntag et al., 2007), which is almost 
exclusively expressed in the membrane of DA neurons projecting to the dorsolateral 
putamen, and are functionally linked to dopamine D2 and GABAB receptors (Sonntag et al., 
2007). 
3.2.2 Co-culture with feeder cells 
Another important strategy to enhance the differentiation toward neuron lineage is co-
culture of ESCs with stromal cell lines such as PA6 (Kawasaki et al., 2000) and MS5 (Barberi 
et al., 2003). This effect of PA6 cells has been named the inductive factor stromal cell-derived 
inducing activity (SDIA) (Mizusekiet et al., 2003; Kawasaki et al., 2000). After screening 
various cell lines, Kawasaki et al found that PA6 stromal cells derived from mouse skull 
bone marrow is a potent inducer of neural differentiation from ESCs (Figure 2). In contrast 
to EB formation protocol, this method does not require growth in serum, the formation of 
EBs, or the selection of neural precursor cells. In this method, ESCs were co-cultured 
without serum on PA6 cells for 8 days in differentiation medium and for an additional 6-12 
days in G-MEM supplemented with N2 and other components. Ninety-two percent of the 
colonies contained differentiated neurons positive for neural markers NCAM, nestin, and 
beta-tubulin III and MAP2 and only less than 2% of the colonies were positive for 
mesodermal and glial markers. 
Co-culturing with stromal cell lines with some modifications has become a common strategy 
to differentiate ESCs into neural cells. In comparison to EB formation protocol, this method 
has fewer steps and is relatively easier and more reproducible for the generation of neural 
precursors and neuronal subtypes (Figure 2). Due to the risk of contamination with animal-
derived components (Martin et al., 2005), some alternative approaches were recently 
developed to use instead of stromal feeders. Human amniotic membrane, the innermost 
layer of placenta has been used as an alternative (Ueno et al., 2006; Niknejad et al., 2008). 
This approach involves the co-culture of matrix layers of human amniotic membrane with 
human ESCs for neural induction. Fifteen days after culturing on amniotic membrane, 
human ESCs produced a population of cells that were greater than 85% nestin positive, and 
many of these formed rosette-like clusters. While this method eliminates the introduction of 
animal-derived products, identification of the factors involved in the regulation of neural 
differentiation, and overcoming inherent limitations in the scale up of processes involving 
cell co-cultures, need to be further addressed. 
Kitajima et al devised a co-culture method for producing neurospheres using PA6 stromal 
cells (Kitajima et al., 2005). To induce neural spheres, ESCs were differentiated on PA6 
stroma for 7 days, detached, dissociated, and cultured in growth medium with FGF-2 and 
EGF. The resulting neurospheres expressed multiple neural markers such as nestin, MAP2 
and GFAP, indicative of a heterogeneous population of neural progenitors, mature neurons, 
and glial cells. Co-culture with PA6 cells for 0-13 days progressively increased the number 
of spheres generated in a time-dependent manner until day 11. The resulting neurospheres 
could be further propagated when switched to a serum-free culture and then differentiated 
into all three neural types. By changing the time of co-culture with PA6 cells, it was also 
possible to induce different proportions of neuronal and glial precursor cells. This system 
thus enabled the production of large numbers of spheres without utilizing EB formation. 
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Also, using MS5 instead of PA6 stromal cells efficiently induced neural differentiation of 
mouse ES cells, and the resulting cells were able to differentiate into more neuronal types 
(GABAergic, sertonergic, dopaminergic and cholinergic neurons) (Barberi et al., 2003). 
Yue et al showed that primate ESCs can differentiate into dopaminergic neurons by 
coculture of ESCs with sertoli cells. Neurons that had been differentiated on sertoli cells 
were positive for Pax2, En1, and AADC; midbrain related markers and negative for 
dopamine-β-hydroxylase, a marker of noradrenergic neurons and could release dopamine 
in vitro when depolarized by KCL (Yue et al., 2006). 
3.2.3 Genetic manipulation 
At this time, EB formation protocol and co-culture with feeder cells typically lead to a mixed 
population of cell types. Moreover, to effectively use this approaches in vitro the dose, order 
of addition, and time of exposure to growth factors are all important parameters that must 
be optimized. This is a difficult task since many of the signals involved in regulating 
neuronal differentiation are only now being elucidated. It seems transfection of key genes 
such as important transcription factors (using conventional DNA delivery, lentiviral and 
adenoviral vectors, and homologous recombination) to ESCs is capable of inducing a 
specific neural lineage and can potentially increase the homogeneity of differentiated cells 
(Figure 2). 
To enhance TH expression in neural stem cells, Sakurada et al used a retrovirus to 
overexpress Nurr1, a transcription factor belonging to the nuclear receptor super family that 
is expressed in midbrain DA neurons. This approach induced TH expression in nearly all 
infected cells in vitro. However, infected cells did not express detectable levels of DOPA, the 
dopamine precursor whose production is catalyzed by TH, and functional production of 
DOPA was only detected when the cells were differentiated with retinoic acid. Even though 
the resulting population uniformly expressed TH, the frequency of neuronal markers within 
these TH positive cells was still low (Sakurada et al., 1999). These results implicate a need 
for additional manipulations to increase neuronal maturation and the functional production 
of dopamine. 
Similar results were observed in neural stem cells derived from E13/E14 rat foetal brain 
tissue, in which Nurr1 overexpression led to an increase in TH expression (Kim et al., 2003). 
However, infected cells did not mature. Park et al used retroviral vectors that co-expressed 
Nurr1 and a second transcription factor to force neuronal differentiation. They examined the 
bHLH transcription factors Mash1, Ngn1, Ngn2 and NeuroD1, all known to induce 
neuronal differentiation (Kageyama& Nakanishi, 1997), and they reported that the induction 
of TH expression depended on which bHLH transcription was co-expressed with Nurr1. 
Ngn1, Ngn2 and NeuroD1 decreased the Nurr1-induced expression of TH, whereas Mash1 
overexpression not only maintained expression but also increased the fraction of cells that 
expressed the neuronal marker Map2ab. Importantly, they showed that the combined 
expression of Mash1 and Nurr1 yielded neurons with electrophysiological properties similar 
to those of mature DA neurons (Park et al., 2006a). 
Furthermore, Park et al showed that when grafted into Parkinsonian rats, cells co-expressing 
Nurr1 and Mash1 reversed behavioral deficits. Intriguingly, a retrovirus encoding Shh, the 
anti-apoptotic protein Bcl-xl, and Nurr1 produced functionally mature dopaminergic 
neurons similar to the Mash1 vector studies (Park et al., 2006b). These studies demonstrate 
the potency of genetic manipulation and highlight the fact that significant additional work 
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will be needed to explore whether extracellular signal combinations can achieve similar 
results. 
In addition to its role in directing differentiation towards a DA phenotype, Nurr1 synergizes 
with Pitx3 to promote terminal maturation of midbrain DA neurons from both mouse and 
human ESCs (Martinat et al., 2006). Lentiviral vectors carrying Nurr1, Pitx3, Lmx1b, or En1 
were introduced at the neural precursor stage after induction into EBs from mouse ESCs. 
The combined transduction of Nurr1 and Pitx3 dramatically induced the expression of the 
late marker DAT (dopamine transporter), but not TH. Only Nurr1 alone induced expression 
of TH. 
The two predominant methods developed on mouse cells, transfection of mouse ESCs with 
specific factors such as Nurr-1 and Lmx1a as well as co-cultures with stromal cells, have 
been translated to human ESCs to direct DA neuron differentiation. Similar results were 
found after human ES cells were transduced with lentiviral vectors carrying both Nurr1 and 
Pitx3 at the neural precursor stage as well as co-cultured with stromal cells (Martinat et al., 
2006). Nurr1 and Pitx3 together promoted the maturation of midbrain DA neurons and led 
to an increase in TH positive cells. In electrophysiological analysis, differentiated human 
ESCs displayed basic neuronal characteristics such as action potentials, burst firing, and 
miniature spontaneous excitatory postsynaptic currents. Transplantation of these cells into a 
mouse model of PD improved some motor ability 6 weeks post-transplantation; however, 
there was limited maturation of the engrafted human ES-derived cells, as assessed by low 
expression of TH 
4. ESCs in PD: hype or hope  
Despite all of the advantages of ESCs for cell replacement therapy, some pitfalls must be 
overcome before ESCs are used therapeutically for PD. The major limitation is ethical issues 
concerning to their embryonic origin. Human embryos are most often destroyed as the stem 
cells are harvested. Hence the question: Can we intentionally kill a developing human being 
at this stage to expand scientific knowledge and potentially provide medical benefit to 
others?  As a result, some regulations limit funding of research to the initial set of derived 
human ESCs, strictly withholding support for the study and derivation of new stem cells 
lines. However, creating new stem lines by deriving human ESCs from single blastomeres 
(Klimanskaya et al., 2006), without destroying the embryo was a promising result to bypass 
the ethical problem of ESCs.  
The other challenge in employing ESCs for developmental biology research and their 
possible application in cell replacement therapy is to direct their wide differentiation 
potential into specific neural cell lineages. The most important concern of the mentioned 
protocols of ESCs differentiation toward specific neural lineages is the nonspecific 
generation of cell populations derived from the three germ layers in the total cell 
population. In all protocols, the presence of mesodermal- and endodermal-originated cell 
lineages is unavoidable, which is undesirable for further application in regenerative 
medicine. Hence, understanding the coordination and roles of intrinsic factors with extrinsic 
factors will be a critical step to direct ESCs differentiation into dopaminergic neuronal cells. 
In addition to mesodermal and endodermal lineages, current protocols result in 
heterogonous population of glia and neural cells, such as serotonergic, GABAergic and 
noradrenergic. To date, it is uncertain which of these ingredients are of positive or negative 
impact on the clinical effectiveness of the transplants. For example in transplantation of 
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foetal mesencephalon which is a mixture of all neural cell types homing to the foetal 
midbrain, containing serotonergic neurons might be responsible for dyskinetic side effects. 
On the other hand, it has been shown that foetal midbrain-derived astrocytes have beneficial 
effects on in vitro differentiation of ESCs into DA neurons. Transplanting a mixture of 
dopaminergic precursors/neurons and midbrain-specific astrocytes might thus be more 
effective than a purified DA cell source. No information is available on the effect of 
GABAergic or noradrenergic neurons also present in midbrain transplants. Therefore, 
further studies will be required to investigate the effects of the other constituents of neural 
cells other than DA neurons on dopaminergic differentiation of ESCs and after grafting in 
the animal model of PD. 
As mentioned, current differentiation protocols rely on the use of animal products (e.g. PA6 
is a mouse stromal cell line) and thus carry the potential to induce disease transmission 
through contamination with bacteria, viruses or other infectious agents, such as those 
responsible for transmissible spongiform encephalopathy. Therefore, animal products 
should, where possible, be replaced by components of human origin and defined and 
feeder-free conditions should be developed for differentiation of ESCs into dopaminergic 
neurons if the cells are going to be implanted in patients.   
The other unresolved problem is whether the grafts will be affected by the PD process. The 
results of foetal mesencephalic tissue transplantations provide evidence that PD pathology 
might propagate from host to graft (Kordower et al., 2008a; Li et al., 2008; Brundin et al., 
2008, Kordower et al., 2008b). However, it seems that at least one decade is required for the 
development of Lewy bodies (LBs) in the grafted cells (Kordower et al., 2008a; Mendez et 
al., 2008). This issue should be noticed in the animal model of PD.  
Rejection of grafts is an important issue in cell replacement therapy, particularly for ESCs 
which are transplanted as an allograft. Although immune responses to brain allografts are 
moderate and survival can be obtained even without immunosuppression (Freed et al., 
2001), most investigators prefer to use immunosuppressive agents for 6 to 12 months after 
transplantation (Brundin etal., 2000, Mendez et al., 2005; Olanow et al., 2003). Another way 
to keep away from immune reactions after transplantation is the using of therapeutic 
cloning. It has been shown that genetically identical ESCs derived DA neurons, generated 
by transfer of autologous nuclei from fibroblasts, improve functional deficits without 
immune reaction in PD mice (Tabar et al. 2008). However, it should be evaluated whether 
genetically modified cells would be acceptable in a clinical protocol. 
Tumor formation remains another obstacle concerning the transplantation of ESCs that has 
to be eliminated before human ESCs can be safely applied in PD. Because life expectancy is 
almost normal in PD patients, even a minor risk of tumor formation associated with cell 
replacement therapy is unacceptable in this disorder. To improve safety, it might be 
necessary to engineer ESCs with regulated suicide genes or to use cell sorting to eliminate 
cells that could give rise to tumors. 
In the end, on the basis of the available experimental data, ESCs are promising source for the 
cell replacement therapy. Although much more studies will be required to overcome the 
mentioned challenging issues, it seems it is now possible to start defining a road map 
including the main steps towards clinical application of ESCs in PD.  
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Parkinson's disease (PD) results primarily from the death of dopaminergic neurons in the substantia nigra.
Current PD medications treat symptoms; none halt or retard dopaminergic neuron degeneration. The main
obstacle to developing neuroprotective therapies is a limited understanding of the key molecular mechanisms
that provoke neurodegeneration. The discovery of PD genes has led to the hypothesis that misfolding of
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dopaminergic neurons. Neurotoxin-based models have been important in elucidating the molecular cascade of
cell death in dopaminergic neurons. PD models based on the manipulation of PD genes should prove valuable
in elucidating important aspects of the disease, such as selective vulnerability of substantia nigra dopaminergic
neurons to the degenerative process.
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